Sage Therapeutics, Inc.
US ˙ NasdaqGM ˙ US78667J1088
QUESTO SIMBOLO NON E' PIU' ATTIVO

SecuritySAGE / Sage Therapeutics, Inc.
InstitutionStrs Ohio
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Strs Ohio closes position in SAGE / Sage Therapeutics, Inc.

On October 30, 2025 - Strs Ohio filed a 13F-HR form disclosing ownership of 0 shares of Sage Therapeutics, Inc. (US:SAGE) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 4, 2025 disclosing 62,200 shares of Sage Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-10-30 2025-09-30 13F SAGE THERAPEUTICS COM_STK 78667J108 0 -100.00 0
2025-08-04 2025-06-30 13F SAGE THERAPEUTICS COM_STK 78667J108 62,200 0 0.00 567 14.78 0.0021
2025-05-28 2025-03-31 13F SAGE THERAPEUTICS COM_STK 78667J108 62,200 62,200 494 0.0021
2024-05-13 2024-03-31 13F SAGE THERAPEUTICS COM 78667J108 0 -7,300 -100.00 0 0.0000
2024-01-30 2023-12-31 13F SAGE THERAPEUTICS COM 78667J108 7,300 0 0.00 0 0.0007
2023-10-26 2023-09-30 13F/A-1 SAGE THERAPEUTICS COM 78667J108 7,300 0 0.00 0 0.0007
2023-10-26 2023-09-30 13F SAGE THERAPEUTICS COM 78667J108 7,300 0 0 0.0007
2023-07-31 2023-06-30 13F SAGE THERAPEUTICS COM 78667J108 7,300 7,300 0 0.0014
2023-01-26 2022-12-31 13F SAGE THERAPEUTICS COM 78667J108 0 -4,700 -100.00 0 -100.00
2022-10-27 2022-09-30 13F SAGE THERAPEUTICS COM 78667J108 4,700 -3,200 -40.51 184 -27.84 0.0009
2022-07-25 2022-06-30 13F SAGE THERAPEUTICS COM 78667J108 7,900 7,900 255 0.0011
2021-10-22 2021-09-30 13F SAGE THERAPEUTICS COM 78667J108 0 -23,093 -100.00 0 -100.00
2021-07-26 2021-06-30 13F SAGE THERAPEUTICS COM 78667J108 23,093 12,050 109.12 1,311 58.72 0.0047
2021-04-23 2021-03-31 13F SAGE THERAPEUTICS COM 78667J108 11,043 11,043 826 0.0031
2020-04-23 2020-03-31 13F SAGE THERAPEUTICS COM 78667J108 0 -52,000 -100.00 0 -100.00
2020-01-24 2019-12-31 13F SAGE THERAPEUTICS COM 78667J108 52,000 -27,642 -34.71 3,753 -66.41 0.0157
2019-10-21 2019-09-30 13F/A-1 SAGE THERAPEUTICS COM 78667J108 79,642 -42,901 -35.01 11,172 -50.21 0.0490
2019-10-21 2019-09-30 13F SAGE THERAPEUTICS COM 78667J108 79,642 27,642 11,172 49,447.8916
2019-07-25 2019-06-30 13F SAGE THERAPEUTICS COM 78667J108 122,543 -76,957 -38.57 22,436 -29.29 0.0998
2019-04-19 2019-03-31 13F SAGE THERAPEUTICS COM 78667J108 199,500 -30,500 -13.26 31,730 44.02 0.1438
2019-01-23 2018-12-31 13F SAGE THERAPEUTICS COM 78667J108 230,000 87,583 61.50 22,031 9.52 0.1118
2018-10-19 2018-09-30 13F SAGE THERAPEUTICS COM 78667J108 142,417 121,206 571.43 20,116 505.90 0.0882
2018-08-06 2018-06-30 13F SAGE THERAPEUTICS COM 78667J108 21,211 -9,289 -30.46 3,320 -32.41 0.0143
2018-04-20 2018-03-31 13F SAGE THERAPEUTICS COM 78667J108 30,500 1,900 6.64 4,912 4.29 0.0217
2018-01-23 2017-12-31 13F SAGE THERAPEUTICS COM 78667J108 28,600 -41,300 -59.08 4,710 8.18 0.0201
2017-10-23 2017-09-30 13F SAGE THERAPEUTICS COM 78667J108 69,900 15,600 28.73 4,354 0.69 0.0187
2017-07-26 2017-06-30 13F SAGE THERAPEUTICS COM 78667J108 54,300 -49,300 -47.59 4,324 -41.27 0.0193
2017-04-26 2017-03-31 13F SAGE THERAPEUTICS COM 78667J108 103,600 200 0.19 7,362 39.46 0.0319
2017-01-24 2016-12-31 13F SAGE THERAPEUTICS COM 78667J108 103,400 5,900 6.05 5,279 17.60 0.0233
2016-10-27 2016-09-30 13F SAGE THERAPEUTICS COM 78667J108 97,500 90,100 1,217.57 4,489 1,794.09 0.0201
2016-04-25 2016-03-31 13F/A-1 SAGE THERAPEUTICS COM 78667J108 7,400 -5,600 -43.08 237 -68.69 0.0011
2016-01-28 2015-12-31 13F SAGE THERAPEUTICS COM 78667J108 13,000 0 0.00 757 37.64 0.0034
2015-10-21 2015-09-30 13F SAGE THERAPEUTICS COM 78667J108 13,000 0 0.00 550 -42.04 0.0026
2015-08-04 2015-06-30 13F SAGE THERAPEUTICS COM 78667J108 13,000 13,000 0.00 949 0.0042
2015-04-27 2015-03-31 13F/A-1 SAGE THERAPEUTICS COM 78667J108 0 -2,000 -100.00 0 -100.00
2015-01-23 2014-12-31 13F SAGE THERAPEUTICS COM 78667J108 2,000 0 0.00 73 15.87 0.0003
2014-10-29 2014-09-30 13F/A-1 SAGE THERAPEUTICS COM 78667J108 2,000 2,000 63 0.0003
2014-10-20 2014-09-30 13F SAGE THERAPEUTICS COM 78667J108 2,000 63
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.